Amsterdam

• Routine versus selective protamine administration to reduce bleeding complications after transcatheter aortic valve implantation Ended
  2023-504205-36-00 11 2023-11-01 Aortic stenosis
• A First in Human Study of IBC-Ab002 in Persons With Early Alzheimer's Disease (AD) Ended
  2024-511770-76-00 1 2023-10-31 Alzheimer's disease
• A Phase 2 Study Evaluating INCB099280 in Participants With Advanced Cutaneous Squamous Cell Carcinoma Ended
  2022-502476-23-00 4 2023-10-25 Treatment of immunotherapy-naive patients with previously untreated or
• A Study to Assess the Effectiveness of BOTOX (Botulinum Toxin Type A) Injections for the Change of Masseter Muscle Prominence in Adult Parti … Ended
  2022-500568-37-00 5 2023-10-11 Masseter Muscle Prominence
• A Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis Ended
  2022-501621-20-00 5 2023-10-02 Prurigo Nodularis
• A clinical study of MK-0616 for people with high amounts of low-density lipoprotein cholesterol Ended
  2022-502782-14-00 5 2023-09-28 Heterozygous Familial Hypercholesterolemia (HeFH)
• A Phase 1/2 Randomized, Blinded, Dose-escalation Study to Evaluate the Safety and Efficacy of Intrathecal Administration of AAV9-ABCD1 Gene … Ended
  2024-518451-39-00 1 2023-09-19 Adrenomyeloneuropathy
• A Study Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Crovalimab for the Management of Acute Uncomplicated Vaso‑O … Ended
  2022-502546-26-00 3 2023-09-11 Sickle Cell Disease
• PREPARE-iVAC Ended
  2023-503894-39-00 11 2023-08-22 kidney transplantation
• A study to evaluate Intravitreal JNJ-81201887(AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary … Ended
  2022-500746-16-00 4 2023-08-11 Geographic Atrophy
• A dose-escalation and expansion study of the safety and pharmacokinetics of XB002 as single-agent and combination therapy in subjects with i … Ended
  2023-508267-69-00 3 2023-08-11 Subjects with Aadvanced solid tumors for whom life-prolonging therapie
• A Phase 2b Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod in Patients with Dementia with Lewy Bodies (DLB) Ended
  2023-504373-20-00 4 2023-08-09 Subjects aged ≥55 years with probable Dementia with Lewy Bodies DLB by
• DiEtary Sodium Intake effects on ertugliflozin-induced changes in GFR, reNal oxygenation and systemic hemodynamics: the DESIGN study, a rand … Ended
  2023-510257-42-01 6 2023-07-25 Type 2 diabetes
• Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD (ACTIVATE study) Ended
  2022-501783-18-00 4 2023-07-21 Parkinson’s Disease
• CC-122 Rollover Study Ended
  2022-501855-97-00 3 2023-06-29 Multiple Myeloma, Follicular Lymphoma, Diffuse Large B-Cell Lymphoma.
• A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors Ended
  2024-517150-10-00 7 2023-06-29 Cancer
• ABTECT-1 – ABX464 Treatment Evaluation for ulcerative Colitis Therapy -1 Ended
  2022-500535-36-01 5 2023-06-12 Moderately to severely active ulcerative colitis
• MERCURI-2 Ended
  2024-515260-31-00 6 2023-06-09 AKI
• A Study of Olezarsen (ISIS 678354) in Participants With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease, or With Severe Hype … Ended
  2022-503022-13-00 5 2023-06-08 Hypertriglyceridemia, Cardiovascular Diseases, Atherosclerosis
• This is a study to evaluate dose-flexibility of Upadacitinib in Adult Subjects with Moderate to Severe Atopic Dermatitis Ended
  2023-504869-23-00 11 2023-05-31 Dermatitis atopic
• A Phase 1/2, Umbrella Study of the Efficacy and Safety of Pembrolizumab plus Enfortumab vedotin +/- Investigational Agents in First-Line met … Ended
  2023-506385-30-00 9 2023-05-22 Advanced Urothelial Carcinoma
• Inhaled Imatinib Pulmonary Arterial Hypertension Clinical Trial – Follow Up Long Term Extension (IMPAHCT-FUL) Ended
  2023-508735-31-00 5 2023-05-05 Pulmonary Arterial Hypertension (PAH)
• A study of efficacy and safety of various treatments in participants with idiopathic pulmonary fibrosis (IPF) Ended
  2023-508729-28-00 4 2023-04-25 Idiopathic pulmonary fibrosis
• A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate Mavacamten in Adults with Cardiomyopathy Ended
  2023-506352-24-00 5 2023-04-13 Non-obstructive Hypertrophic Cardiomyopathy

Showing 961–984 of 1,112 trials